Result: 41 - 60 of 76
DRAMP IDNAMEDescriptionMedical_useStage of developmentCompany
DRAMP18152IMX942Synthetic cationic host defense peptide,derivative of IDR-1 and indolicidinNosocomial infections, febrile,neutropeniaPhase IIInimex
DRAMP18153Opebacan21-amino-acid peptide derivative of bactericidal/permeability-increasing proteinEndotoxemia in hematopoetic,stem cell transplant,recipientsPhase I/IIXoma
DRAMP18154XOMA-6299-amino-acid peptide derivative of bactericidal/permeability-increasing proteinImpetigoPhase IIAXoma
DRAMP18155DiaPep277HSP60 derivative (24-mer peptide) that induces T regulatory cellsType 1 diabetes mellitusPhase IIIDeveloGen
DRAMP18156RDP58(Delmitide)Semisynthetic D-amino acid decapeptide derived from HLA class I B2702Inflammatory bowel diseasePhase II (Completed)Genzyme; licensed to Procter&Gamble
DRAMP18157Novexatin(NP213)cyclic cationic peptide derived from NovaBiotics arginine peptide platformtreatment of dermatophyte fungal infections such as onychomycosisPhase IIbUnknown
DRAMP18158PMX-30063(brilacidin)Defensin structural mimetic, non-peptide,small molecule/copolymerAcute bacterial skin infections caused by StaphylococcussppPhase IIPolyMedix
DRAMP18159Pexiganan acetate [MSI-78]Synthetic cationic host defense peptide(22-mer), magainin derivativeTopical antibioticPhase IIIFaliureMacroChem
DRAMP18161OP-145 (24-mer peptide)Synthetic 24-mer peptide derived from LL-37 for binding to lipopolysaccharides or lipoteichoic acidChronic bacterial middle ear infection.Phase II (Completed)OctoPlus; Leiden University (the Netherlands).
DRAMP18162BL2060Synthetic compound comprising fatty acid and lysine copolymersAnti-infectiveLead optimizationBioLineRx (Jerusalem).
DRAMP18163GhrelinEndogenous host-defence peptide,Synthetic constructAirway inflammation, chronic respiratory infection and cystic fibrosisPhase II (Completed)University of Miyazaki Third Department of Internal Medicine (Japan) and Papworth Hospital (UK).
DRAMP18164AP-214Synthetic derivative from HDP α-melanocyte-stimulating hormoneSepsis and post-surgical organ failurePhase II (Completed)Action Pharma A/S (Aarhus and Copenhagen, Denmark)
DRAMP18165CD-NPSynthetic chimeric 37-mer derived from combination of two natriuretic peptidesAcute decompensated failure (ADHF),Organ failurePhase IINile Therapeutics (United States, Minnesota).
DRAMP18166Vasoactive intestinal peptide (VIP; Endogenous HDP)No more descriptionAcute Respiratory Distress Syndrome and SepsisPhase IStony Brook University and State University of New York (United States, New York).
DRAMP18167Ruminococcin C (Bacteriocin)Ruminococcus gnavus E1Gastrointestinal tract infections; Stomach and intestine infections (Rat model; In-vivo)PreclinicalUnknown
DRAMP18168Planosporicin (Bacteriocin)Planomonospora sp. DSM14920Hospital-acquired infections; Multi-drug resistant strain (Murine model; In-vivo)PreclinicalUnknown
DRAMP18169ESL5Enterococcus faecalis SL-5Gastrointestinal tract infections; Stomach and intestine infections (Human model; In-vivo)PreclinicalUnknown
DRAMP18170Colicin E1 (Bacteriocin)Escherichia coli H22Gastrointestinal tract infections; Stomach and intestine infections (Murine model; In-vivo) PreclinicalUnknown
DRAMP18171Lactocin 160 (Bacteriocin)Lactobacillus rhamnosus 160Urogenital tract infections; Bacterial vaginosisPreclinicalUnknown
DRAMP18172Bacteriocin OR-7Lactobacillus salivarius NRRL B-30514Gastrointestinal tract infections; Campylobacter infection (Chicken model; In-vivo)PreclinicalUnknown
Disclaimer:
The Website is provided “as is” and the DRAMP hereby disclaim all warranties of any kind, express or implied. The DRAMP does not make any warranty that the services will be free of errors. You understand that you download from, or otherwise obtain content or services through, the DRAMP at your own discretion and risk.
Close
Sign in     login

Forgot your password?